Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Multi-tRNA Synthetase Complex (MSC) Research.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for JTV1/AIMP2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Wild-Type) | JTV1/AIMP2 Recombinant Protein (Full Length) High purity (>95%), Endotoxin <1.0 EU/μg. Sequence Verified. E. coli expressed. |
View AIMP2 Products |
| Antigen (Spliced Variant) | AIMP2-DX2 Recombinant Protein (Oncogenic Splicing Isoform) High purity (>95%), Sequence Verified by Mass Spectrometry. |
View AIMP2-DX2 Products |
| Gene Delivery | JTV1/AIMP2 Promise-ORF / Lentivirus Full-length ORF for stable intracellular overexpression and cell-line construction. |
View AIMP2 Products |
| Benchmark Ab | Anti-AIMP2 Recombinant Antibody Recombinant positive control for Western Blot, ELISA, and IP validation. |
View AIMP2 Products |
| Validator | JTV1/AIMP2 siRNA Set For target knockdown and specificity verification in phenotypic assays. |
View AIMP2 Products |
| Related Target A | KARS (Lysyl-tRNA Synthetase) Interacts with AIMP2 within the MSC; key driver of cancer cell migration and metastasis. |
View KARS Products |
| Related Target B | IARS (Isoleucyl-tRNA Synthetase) Core structural component of the Multi-tRNA Synthetase Complex, synergistic target in translation regulation. |
View IARS Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Differentiating AIMP2-WT from oncogenic AIMP2-DX2 | Sequence-verified recombinant AIMP2-WT and AIMP2-DX2 proteins strictly characterized by mass spectrometry. |
| Protein-Protein Interaction (PPI) screening in vitro | High-purity, endotoxin-controlled recombinant proteins with native-like solubility to minimize aggregate-induced false positives. |
| Lack of functional validation controls | Sequence-verified biosimilar antibodies and validated siRNA sets included for target specificity confirmation. |
| Stable cell line construction for phenotypic screening | High-titer, integration-ready Lentiviral Particles optimized for stable intracellular expression. |
Live JTV1/AIMP2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for JTV1/AIMP2 therapeutics is intensifying, with major players shifting focus from traditional multi-synthetase complex biology to selective inhibition of the oncogenic splice variant, AIMP2-DX2. As first-generation therapies targeting protein-protein interactions (PPI) reach preclinical and early clinical milestones, the next wave of R&D is targeting selective degradation via PROTACs and molecular glues to overcome chemoresistance in solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule PPI Inhibitors | Biocon, Daewoong Pharmaceutical | Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer | Selectivity Assay (Need both WT AIMP2 and DX2 mutant proteins to rule out wild-type toxicity) |
| PROTACs / Degraders | Academic Spin-offs, Biotech Startups | Chemoresistant Solid Tumors | Ubiquitination & Degradation Assay (Need stable AIMP2/AIMP2-DX2 expressing cell lines via Lentivirus) |
| RNA Therapeutics (siRNA/ASO) | Translational Medicine Institutes | Refractory Cancers | Target Knockdown Validation (Need sequence-specific siRNA sets and high-purity qPCR/WB control antigens) |